Video

Susan Moore on Nonadherence to Oral Oncolytics

Susan Moore on Effects of Nonadherence to Oral Oncolytics

Susan Moore, RN, MSN, ANP, AOCN® Oncology Nurse Practitioner/Consultant at MCG on the effects of nonadherence to oral oncolytics.

Moore says an effect of nonadherence to oral oncolytics can be a lowered efficacy. All of the data given to a patient that illustrates a certain success or survival rate is dependent upon the completion of treatment regimens. The rate given to patients is based on full compliance, not if a patient, for example, takes the medication for six months then stops for three months and starting again. It is based on taking the medicine every day, or as ordered, for the length of time that it is ordered.

Another effect occurs when patients do not take medications as ordered: increased toxicity. When patients take too much medication or continue taking it when told to stop, they can have increased toxicity, or end up with toxicities that are so severe that the medication has to be stopped because of the toxicity and not because it stopped working.

Related Videos
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Stephen J. Freedland, MD
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic